Low-Dose Isotretinoin Shows Promise for Moderate to Severe Seborrheic Dermatitis
- In:
Clinical Practice,
Professional Development
A recent study compared daily 10 mg vs 20 mg isotretinoin in patients with moderate to severe seborrheic dermatitis (SD). Among 234 patients treated for at least three months, the 20 mg dose led to greater improvements in disease severity, quality of life, and patient satisfaction after 12 months. Recurrence rates were also significantly lower with the higher dose, though side effects like muscle pain and nosebleeds were more common.
These findings of the retrospective observational analysis support 20 mg isotretinoin as a more effective option for long-term SD control, though further research is needed to refine dosing and maintenance strategies.
Click here for a link to the original article.
Elevate-Derm Alliance Editorial Committee